

Please amend claims 1, 2, 6 and 10 as follows:

1. (Three times amended) A peptide of the formula: $R^1 - X^1 - X^2 - R^2$

wherein X^1 is phenyl alanine;

X^2 is any amino acid residue;

R^1 is NH_2^- or an amino acid sequence $X^3 - X^4 - X^5$

wherein X^3 is an aliphatic amino acid residue having a side chain hydroxyl group

and X^4 and X^5 are the same or different and are any amino acid residue and wherein R^2 is a sequence of 1 to 3 amino acid residues which are the same or different and are aliphatic amino acid residues provided that the peptide is not Phe-Glu-Gly, Phe-Ala-Gly [or], Phe-Ala-Gly-Gly or Phe-Ala-Ala-Ala.

2. (Three times amended) A peptide of the formula: $R^1 - X^1 - X^2 - R^2$

wherein X^1 is phenyl alanine;

X^2 is Glu or Ala;

R^2 is Gly-Gly;

R^1 is $X^3 - X^4 - X^5$ wherein

X^3 is Thr,

X^4 is Asp or Ala and

X^5 is Ile or Ala.

E 2
6. (Twice amended) The peptide of claim 2 having an amino acid sequence selected from the group consisting of:

- (a) Phe-Glu-Gly-Gly-Gly (Sequence ID NO:9);
- (b) Phe-Glu-Gly-Gly (Sequence ID NO:11);
- (c) Phe-Ala-Gly-Gly-Gly (Sequence ID NO:12); and
- (d) Phe-Glu-Sarcosine.

E 3
10. (Three times amended) The peptide of claim 6 wherein Phe and [Glu] Glu or Ala are D amino acids.

Please add new claims 31-36 as follows:

E 4
--31. The pharmaceutical composition of claim 12 wherein the peptide comprises at least one D amino acid.

32. The pharmaceutical composition of claim 12 wherein the peptide is selected from the group consisting of:

- (a) Phe-Glu-Gly;
- (b) Thr-Asp-Ile-Phe-Glu-Gly-Gly (Sequence ID NO:8);
- (c) Thr-Ala-Ile-Phe-Glu-Gly-Gly (Sequence ID NO:3);
- (d) Thr-Asp-Ala-Phe-Glu-Gly-Gly (Sequence ID NO:4); and
- (e) Thr-Asp-Ile-Phe-Ala-Gly-Gly (Sequence ID NO:6).

33. The pharmaceutical composition of claim 12 wherein the peptide is Phe-Glu-Gly and wherein Phe and Glu are D amino acids.

34. A method for treating or preventing SIRS-induced hypotension in a mammal comprising administering to the mammal an effective amount of a peptide selected from the group consisting of

*E 4
cont*

- (a) Phe-Glu-Gly;
- (b) Thr-Asp-Ile-Phe-Glu-Gly-Gly (Sequence ID NO:8);
- (c) Thr-Ala-Ile-Phe-Glu-Gly-Gly (Sequence ID NO:3);
- (d) Thr-Asp-Ala-Phe-Glu-Gly-Gly (Sequence ID NO:4);
- (e) Thr-Asp-Ile-Phe-Ala-Gly-Gly (Sequence ID NO:6); and
- (f) Phe-Glu-Gly wherein Phe and Glu are D amino acids,

or an effective fragment or derivative of said peptide.

35. A method for treating or preventing anaphylactic hypotension in a mammal comprising administering to the mammal an effective amount of a peptide selected from the group consisting of

- (a) Phe-Glu-Gly;
- (b) Thr-Asp-Ile-Phe-Glu-Gly-Gly (Sequence ID NO:8);
- (c) Thr-Ala-Ile-Phe-Glu-Gly-Gly (Sequence ID NO:3);
- (d) Thr-Asp-Ala-Phe-Glu-Gly-Gly (Sequence ID NO:4);

(e) Thr-Asp-Ile-Phe-Ala-Gly-Gly (Sequence ID NO:6); and
(f) Phe-Glu-Gly wherein Phe and Glu are D amino acids,
or an effective fragment or derivative of said peptide.

36. A method for treating or preventing an anaphylactic reaction in a mammal comprising administering to the mammal an effective amount of a peptide selected from the group consisting of

*E 4
Cont*

- (a) Phe-Glu-Gly;
- (b) Thr-Asp-Ile-Phe-Glu-Gly-Gly (Sequence ID NO:8);
- (c) Thr-Ala-Ile-Phe-Glu-Gly-Gly (Sequence ID NO:3);
- (d) Thr-Asp-Ala-Phe-Glu-Gly-Gly (Sequence ID NO:4);
- (e) Thr-Asp-Ile-Phe-Ala-Gly-Gly (Sequence ID NO:6); and
- (f) Phe-Glu-Gly wherein Phe and Glu are D amino acids,

or an effective fragment or derivative of said peptide.--